RxDoctor Payments DataLook up a doctor →

Anthony Dimatteo, DO

Urology · Butler, PANPI 1356601405

Payments from drug & device makers

$189,042in general payments, 2019–2025

Across 562 payments — averaging $336.37 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Teleflex LLC$181K
  • Johnson & Johnson$2K
  • Sumitomo Pharma America, Inc.$962
  • Medtronic$928
  • Myovant Sciences Inc.$822
  • Pfizer$646
  • plus $3K from 21 others

What the payments were for

  • Consulting fees$30,55816%
  • Speaking & faculty fees$136,24472%
  • Travel & lodging$11,8906%
  • Food & beverage$10,2085%
  • Education$1420%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$189,042 in reported general payments places this provider in the 95th percentile of 596 urology providers in Pennsylvania.

See all urology providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$214,645
Medicare patients
489
Services billed
7,211

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OrgovyxRelugolix71$191,139
MyrbetriqMirabegron107$68,785
GemtesaVibegron84$48,360
Mirabegron ErMirabegron33$13,755
Tamsulosin Hcl296$3,257
Potassium Citrate ErPotassium Citrate32$3,015
Solifenacin Succinate143$2,555
Methenamine Hippurate43$1,756
Estradiol15$1,274
Trimethoprim15$714
Finasteride41$663
Dutasteride13$383
Clotrimazole19$327
Ciprofloxacin Hcl63$118
Oxybutynin Chloride24$108

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Sumitomo Pharma America, Inc.Orgovyx, Gemtesa$962$239,499155 claims
Astellas Pharma US IncMyrbetriq$354$68,785107 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 596 urology providers in Pennsylvania.

Other urology in Butler

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →